Tools · FilingsUpdated with annual filings
Japan Cross-Holdings Unwind
Annual changes in strategic shareholdings, disposals and carrying amounts.
Data through · Updated with annual filings
1 row matches “4503” · Clear · Go to Astellas Pharma (4503) →
Fiscal years ending in 2026
Sellers league
1| Company | Sale proceeds | Issuers sold down | Balance-sheet value | % of consolidated net assets | Holdings (issuers) | Filing |
|---|---|---|---|---|---|---|
| Astellas Pharma4503 · アステラス製薬 | — | — | ¥1.78bn | 0.10% | 2 | Filed — filing S100YBPK |
Issuers sold down
1| Company | Sale proceeds | Issuers sold down | Balance-sheet value | % of consolidated net assets | Holdings (issuers) | Filing |
|---|---|---|---|---|---|---|
| Astellas Pharma4503 · アステラス製薬 | — | — | ¥1.78bn | 0.10% | 2 | Filed — filing S100YBPK |
Largest remaining books
1| Company | Sale proceeds | Issuers sold down | Balance-sheet value | % of consolidated net assets | Holdings (issuers) | Filing |
|---|---|---|---|---|---|---|
| Astellas Pharma4503 · アステラス製薬 | — | — | ¥1.78bn | 0.10% | 2 | Filed — filing S100YBPK |
Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.
Related tools
Tender offers
Tender offer prices, windows, conditions and disclosed outcomes.
Activist & 5% stakes
Disclosed stakes above 5%, with activist groups and ownership changes.